ArticleACS omega2026
PDGFR-Targeted Ruxolitinib Liposomes Modulate Fibroblast-Associated Colorectal Cancer-Stroma Interactions, Reducing Invasion and Enhancing Chemosensitivity.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruxolitinib (Rux) is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways and is clinically used for the treatment of myelofibrosis. In this study, a nanodelivery approach was developed to investigate the effects of Rux on fibroblast-associated tumor-stroma interactions in colorectal cancer. Platelet-derived growth factor receptor (PDGFR)-targeted, Rux-loaded liposomes (Lip/Rux/PDGFR) were prepared using a lipid thin-film hydration method and characterized by dynamic light scattering. The average hydrodynamic diameters of Lip/Rux and Lip/Rux/PDGFR were 186.2 ± 1.2 nm and 178.6 ± 2.0 nm, respectively, with slightly negative surface charges. Transmission electron microscopy confirmed the spherical morphology. Antiproliferative activity was evaluated in HT-29 colorectal cancer cells using MTT and three-dimensional tumor spheroid assays. Lip/Rux and Lip/Rux/PDGFR reduced HT-29 cell viability compared with free Rux and Lip/PDGFR controls. To assess stromal-associated effects, activated fibroblasts were treated and subsequently evaluated in coculture and 3D spheroid invasion models. Treatment of activated fibroblasts with Lip/Rux/PDGFR was associated with a greater reduction in HT-29 cell invasion than free Rux and Lip/PDGFR. Furthermore, pretreatment of activated fibroblasts with Lip/Rux/PDGFR was associated with improved 5-FU responsiveness in cocultured HT-29 spheroids, suggesting a reduction in fibroblast-associated chemoprotective effects. Taken together, these findings suggest that PDGFR-targeted liposomal delivery of Rux may affect fibroblast-associated tumor-stroma interactions, which could contribute to reduced colorectal cancer cell invasion and enhanced sensitivity to chemotherapy. Further studies are needed to clarify the underlying mechanisms and determine whether these effects are mediated through alterations in activated fibroblast functions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.